Sort   by:  
 Page size 
ModelsGrange2001 - L Dopa PK model
Grange2001 - L-dopa PK model A pharmacokinetics of L-dopa in rats after administration of L-dopa alone (this model: BIOMD0000000321) or L-dopa combined with a peripheral AADC (amino-acid-decarboxylase) inhibitor (BIOMD0000000320) has been studied using noncompartmental analysis. ...
2024-09-02 | BIOMD0000000321 | BioModels
ModelsGrange2001 - PK interaction of L-dopa and benserazide
Grange2001 - PK interaction of L-dopa and benserazide A pharmacokinetics of L-dopa in rats after administration of L-dopa alone (BIOMD0000000321) or L-dopa combined with a peripheral AADC (amino-acid-decarboxylase) inhibitor (this model: BIOMD0000000320) has been studied using nonc...
2024-09-02 | BIOMD0000000320 | BioModels
TranscriptomicsRNA-SEQ of WT and iMSN-D2RKO Parkinson's mice model treated with L-dopa
We analyzed the RNA expression profiles of Parkinson's model (6-hydroxydopamine lesion, 6-OHDA) mice in two different genotypes, WT and iMSN-D2RKO mice. Mutant iMSN-D2RKO mice were generated by mating D2Rflox/flox males with D2Rflox/flox females carrying the CRE under the control of the D1 receptor ...
ORGANISM(S): Mus musculus 
2023-06-06 | E-MTAB-11848 | biostudies-arrayexpress
TranscriptomicsCandida albicans DOPA-grown cells
The fungal pathogen Candida albicans produces dark-pigmented melanin when grown in a basal medium containing 1 mM l-DOPA as melanin substrate. In the widely used C. albicans strain SC5314, melanin appeared after 3-4 days of incubation in l-DOPA medium. The experiment was designed to reveal cadidat...
ORGANISM(S): Candida albicans 
2010-07-07 | E-GEOD-20338 | biostudies-arrayexpress
GenomicsGenomics analysis of L-DOPA exposure in Drosophila sechellia
Genomics analysis of L-DOPA exposure in Drosophila sechellia
PRJNA574647 | ENA
ProteomicsA novel method for creating a synthetic L-DOPA proteome and in vitro evidence of incorporation.
Proteinopathies are protein misfolding diseases that have an underlying factor that effect the conformation of proteoforms. A factor hypothesised to play a role in these diseases is the incorporation of non-protein amino acids into proteins, with a key example being the therapeutic drug levodopa. Th...
ORGANISM(S): Homo sapiens (Human) 
2022-02-17 | PXD025759 | Pride
Misincorporation  post translational modifications  ptm  levodopa  l-dopa 
GenomicsL-DOPA treatment promotes sustained neurovascular and synaptic homeostasis in the diabetic retina
L-DOPA treatment promotes sustained neurovascular and synaptic homeostasis in the diabetic retina
PRJNA1420788 | ENA
TranscriptomicsL-DOPA treatment promotes sustained neurovascular and synaptic homeostasis in the diabetic retina
Purpose: Previous work has shown a sustained protective effect of levodopa (L-DOPA) on retinal function in early-stage diabetic retinopathy in humans. Here, we quantify neurovascular function, investigate the longevity of L-DOPA treatment for sustained retinal protection, and assess gene expression ...
ORGANISM(S): Mus musculus 
2026-07-20 | GSE318897 | GEO
ProteomicsIntegrative Proteome and Metabolomics Analyses of Cryptococcus neoformans Responses to Melanin Substrates Niger seed and L-DOPA
Melanin, as a pivotal antioxidant pigment, plays a critical role in the pathogenicity of Cryptococcus neoformans. However, the underlying signaling pathways responsible for melanin biosynthesis in C. neoformans are not yet fully elucidated. In this study, proteome and metabolomics analyses were cond...
ORGANISM(S): Cryptococcus neoformans var. grubii serotype A (strain H99 / ATCC 208821 / CBS 10515 / FGSC 9487) (Filobasidiella neoformans var. grubii) 
2025-07-23 | PXD056054 | Pride
Cryptococcus neoformans  melanin biosynthesis  substrate-dependent manner  substrate-independent manner 
GenomicsParkinson’s disease and melanoma: mechanistically linked via L-DOPA treatment and pheomelanin carcinogenicity
Parkinson’s disease and melanoma: mechanistically linked via L-DOPA treatment and pheomelanin carcinogenicity
PRJNA1466553 | ENA
Sort   by:  
 Page size